ARGX
Price:
$611.01
Market Cap:
$36.89B
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-...[Read more]
Industry
Biotechnology
IPO Date
2017-05-18
Stock Exchange
NASDAQ
Ticker
ARGX
According to argenx SE’s latest financial reports and current stock price. The company's current ROE is -2.75%. This represents a change of 128.38% compared to the average of -1.20% of the last 4 quarters.
The mean historical ROE of argenx SE over the last ten years is -21.87%. The current -2.75% ROE has changed -87.45% with respect to the historical average. Over the past ten years (40 quarters), ARGX's ROE was at its highest in in the December 2020 quarter at 14.04%. The ROE was at its lowest in in the December 2015 quarter at -13.26%.
Average
-21.87%
Median
-18.35%
Minimum
-41.08%
Maximum
-7.20%
Discovering the peaks and valleys of argenx SE ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 149.96%
Maximum Annual ROE = -7.20%
Minimum Annual Increase = -75.87%
Minimum Annual ROE = -41.08%
Year | ROE | Change |
---|---|---|
2023 | -7.20% | -71.45% |
2022 | -25.22% | 56.54% |
2021 | -16.11% | -58.44% |
2020 | -38.77% | 149.96% |
2019 | -15.51% | 25.30% |
2018 | -12.38% | 52.07% |
2017 | -8.14% | -75.87% |
2016 | -33.73% | -17.89% |
2015 | -41.08% | 99.45% |
2014 | -20.59% | -27.09% |
The current ROE of argenx SE (ARGX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-16.18%
5-year avg
-20.56%
10-year avg
-21.87%
argenx SE’s ROE is greater than IVERIC bio, Inc. (-39.26%), greater than Blueprint Medicines Corporation (-47.66%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Karuna Therapeutics, Inc. (-25.23%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Legend Biotech Corporation (-29.69%), greater than Zai Lab Limited (-36.97%), greater than Seagen Inc. (-16.53%), less than Alnylam Pharmaceuticals, Inc. (323.66%), less than Ascendis Pharma A/S (212.63%), greater than Vaxcyte, Inc. (-23.53%), greater than Travere Therapeutics, Inc. (-541.59%), greater than Akero Therapeutics, Inc. (-32.52%), greater than BeiGene, Ltd. (-25.12%),
Company | ROE | Market cap |
---|---|---|
-39.26% | $5.51B | |
-47.66% | $6.01B | |
-85.39% | $334.51M | |
-25.23% | $12.60B | |
-22.40% | $1.36B | |
-40.45% | $4.12B | |
-32.76% | $558.90M | |
-103.92% | $4.36B | |
-29.69% | $7.64B | |
-36.97% | $3.13B | |
-16.53% | $43.15B | |
323.66% | $33.00B | |
212.63% | $7.91B | |
-23.53% | $11.47B | |
-541.59% | $1.63B | |
-32.52% | $2.17B | |
-25.12% | $23.14B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like argenx SE using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like argenx SE or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is argenx SE's ROE?
How is the ROE calculated for argenx SE (ARGX)?
What is the highest ROE for argenx SE (ARGX)?
What is the 3-year average ROE for argenx SE (ARGX)?
What is the 5-year average ROE for argenx SE (ARGX)?
How does the current ROE for argenx SE (ARGX) compare to its historical average?